Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients (3T Stroke-Ⅲ)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1630 participants.

Also called NCT05745259

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,630 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05745259
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05745259. Randomized; single masking; primary purpose treatment. Start 2022-10-26 (actual); primary completion 2023-11-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients (3T Stroke-Ⅲ)
Condition
Acute Ischemic Stroke
Intervention (Drug)
Alteplase
Intervention (Drug)
Tenecteplase
Lead sponsor
Beijing Tiantan Hospital (class: other)
Collaborator
Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd (class: not stated)
Collaborator
The Place Pharmaceutical(Jiangsu) Co., Ltd (class: not stated)

Record details

Record id
cardio:ct-nct05745259
Content hash
7283bd8a2f946669f3e85afc9a5196daf3301a49a3c3d9b5b3d7e71a47014de6